NCT07450976 2026-03-12
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Not yet recruiting
Clinical Trials
38 trialsNCT06760819 2026-03-04
panSOHO
Bayer
Phase 2 Recruiting
NCT05775159 2026-02-18
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
Phase 2 Recruiting
NCT06219941 2026-02-12
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
Phase 2 Recruiting
NCT07398339 2026-02-09
DVDMS
Shanghai Guangsheng Biopharmaceutical Co., Ltd
Phase 2 Recruiting
NCT05512377 2026-01-21
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
Phase 2 Completed
NCT05998447 2025-12-16
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
Genome & Company
Phase 2 Terminated
NCT05733598 2025-12-15
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune Inc.
Phase 2 Recruiting
NCT03797326 2025-11-17
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02576431 2025-11-12
NAVIGATE
Bayer
Phase 2 Completed
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT04466891 2025-09-15
HERIZON-BTC-01
Jazz Pharmaceuticals
Phase 2 Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT02711553 2025-08-03
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
Phase 2 Active not recruiting
NCT04571710 2025-07-24
A Trial of SHR1258 in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Withdrawn
NCT05489211 2025-07-11
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT06778031 2025-03-06
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT06465563 2025-01-27
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT04910386 2024-08-14
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
3D Medicines
Phase 2 Not yet recruiting
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT04677504 2024-07-03
A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT04329429 2023-12-20
A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
RemeGen Co., Ltd.
Phase 2 Unknown
NCT03230318 2023-12-19
FIDES-01
Basilea Pharmaceutica
Phase 2 Completed
NCT03833661 2023-10-25
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
EMD Serono
Phase 2 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT03999658 2023-05-01
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Sorrento Therapeutics, Inc.
Phase 2 Withdrawn
NCT03790111 2023-04-19
TELE-ABC
TerSera Therapeutics LLC
Phase 2 Terminated
NCT04784520 2023-02-06
A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Terminated
NCT05041972 2022-09-13
ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Ambrx, Inc.
Phase 2 Withdrawn
NCT04838964 2021-12-29
A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
Shanghai Miracogen Inc.
Phase 2 Unknown
NCT04837508 2021-12-10
A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
Shanghai Miracogen Inc.
Phase 2 Unknown
NCT01773785 2021-10-13
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT04186156 2021-02-03
A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer
Karus Therapeutics Limited
Phase 2 Withdrawn
NCT02579616 2020-12-23
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
Eisai Inc.
Phase 2 Completed
NCT02966821 2019-02-27
Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
Hutchmed
Phase 2 Completed
NCT01943864 2017-05-31
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
GlaxoSmithKline
Phase 2 Completed
NCT00753675 2016-10-10
VANGOGH
Sanofi
Phase 2 Completed
NCT00380588 2009-11-20
Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer
Eli Lilly and Company
Phase 2 Completed